Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2038658 | 0.82 | ALDH1A1 (0.54) | CNR1TSHRCNR2ALDH1A1MAPT | |
| SCHEMBL2042835 | 0.81 | CNR1 (0.46) | CNR1TSHRNPSR1CNR2ALDH1A1 | |
| SCHEMBL1983582 | 0.81 | CNR2 (0.49) | POLBCNR1NPSR1CNR2ALDH1A1 | |
| SCHEMBL23809280 | 0.79 | CNR1 (0.45) | CNR1TSHRNPSR1CNR2ALDH1A1 | |
| SCHEMBL2036074 | 0.78 | P2RX7 (0.47) | CNR1CNR2ALDH1A1MAPTMEN1 | |
| SCHEMBL2035808 | 0.78 | CNR1 (0.44) | CNR1TSHRCNR2ALDH1A1MAPT | |
| SCHEMBL2040518 | 0.77 | CNR1 (0.45) | CNR1TSHRCNR2ALDH1A1MAPT | |
| SCHEMBL2038751 | 0.76 | ALDH1A1 (0.46) | CNR1CNR2ALDH1A1MAPTMEN1 | |
| SCHEMBL1985481 | 0.76 | ALDH1A1 (0.46) | CNR1CNR2ALDH1A1MAPTMEN1 | |
| SCHEMBL2035126 | 0.75 | TPSAB1 (0.43) | CNR1TSHRNPSR1CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516419-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| WO-2011079102-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | POLB 3685/4885CNR1 160/4885TSHR 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.